Prohibits substitution of prescribed epilepsy drugs by pharmacists without prior notification to and written consent of physician and patient.

This New Jersey bill requires pharmacists to obtain written consent from both the prescribing physician and the patient (or their parent/guardian/spouse) before substituting any brand or generic anti-epileptic drug for epilepsy treatment. It prohibits pharmacists from changing the prescribed drug formulation, manufacturer, or brand without this prior notification and consent. The law directly affects epilepsy patients, their doctors, and pharmacists by mandating collaborative decision-making for medication substitutions. The policy aims to prevent potential risks from switching anti-epileptic drugs, which can impact seizure control due to sensitivity in drug concentrations. The bill is currently pending in the Assembly Health Committee after introduction on January 13, 2026.